The simple, non-invasive, and accurate diagnostic solution for Alzheimer’s disease (AD) can distinguish patients with AD from healthy people and evaluate disease status from a single drop of blood, with more than 96% accuracy. This cutting-edge technology can be applied towards developing a clinical tool for population-scale screening, early diagnosis, staging and monitoring of the disease.
Alzheimer’s disease is the most common cause of dementia, affecting more than 50 million people globally. Detecting and treating AD remains a significant challenge. This simple and robust blood test for early AD diagnosis and progression monitoring, can address unmet medical need.
Hong Kong Center for Neurodegenerative Diseases (HKCeND) was established under the government-funded InnoHK initiative. HKCeND harnesses the power of science to make a translational impact in the development of innovative diagnostic tools and therapeutic strategies for neurodegenerative diseases.
Building on the pioneering work of HKUST’s State Key Laboratory of Molecular Neuroscience led by neuroscientist Prof. Nancy Ip, HKCeND has fostered cross-institutional R&D collaboration with University College London and Stanford University.
This interdisciplinary collaboration is bringing together prominent scientists in the areas of neuroscience, stem cell biology and artificial intelligence to advance cutting-edge research and deliver promising breakthroughs that improve and transform the live of people worldwide.